Immuron Ltd ADR (IMRN) - Cash Flow Conversion Efficiency
Based on the latest financial reports, Immuron Ltd ADR (IMRN) has a cash flow conversion efficiency ratio of -0.186x as of December 2025. Cash flow conversion efficiency measures how effectively a company's net assets (equity) generate operating cash flow. It is calculated by dividing operating cash flow ($-2.43 Million) by net assets ($13.06 Million). A higher ratio indicates that the company is more efficient at using its equity to generate cash flow from its core operations. See IMRN net asset quality score to measure how much of total assets are equity-financed.
Immuron Ltd ADR - Cash Flow Conversion Efficiency Trend (2001–2025)
This chart illustrates how Immuron Ltd ADR's cash flow conversion efficiency has evolved over time, based on yearly financial data. Explore Immuron Ltd ADR long-term investment allocation to see how much of total assets are deployed in long-term investments.
Immuron Ltd ADR Competitors by Cash Flow Conversion Efficiency
The table below lists competitors of Immuron Ltd ADR ranked by their cash flow conversion efficiency.
| Company | Cash Flow Conversion Efficiency |
|---|---|
|
Sahakol Equipment Public Company Limited
BK:SQ
|
0.164x |
|
Ambow Education Holding Ltd
NYSE MKT:AMBO
|
0.153x |
|
Jayud Global Logistics Limited Class A Ordinary Shares
NASDAQ:JYD
|
-0.365x |
|
Plant Advanced Technologies SA
PA:ALPAT
|
0.000x |
|
Sewon E&C
KO:091090
|
-0.052x |
|
AHB Holdings Bhd
KLSE:7315
|
-0.046x |
|
Halfords Group PLC
LSE:HFD
|
0.193x |
|
Zonte Metals Inc
V:ZON
|
0.000x |
Annual Cash Flow Conversion Efficiency for Immuron Ltd ADR (2001–2025)
The table below shows the annual cash flow conversion efficiency of Immuron Ltd ADR from 2001 to 2025. For the full company profile with market capitalisation and key ratios, see IMRN market cap overview.
| Year | Net Assets | Operating Cash Flow | Cash Flow Conversion Efficiency | Change |
|---|---|---|---|---|
| 2025-06-30 | $8.03 Million | $-6.14 Million | -0.764x | -65.15% |
| 2024-06-30 | $12.71 Million | $-5.88 Million | -0.463x | -264.71% |
| 2023-06-30 | $19.62 Million | $-2.49 Million | -0.127x | +6.13% |
| 2022-06-30 | $23.18 Million | $-3.13 Million | -0.135x | -14.89% |
| 2021-06-30 | $25.90 Million | $-3.05 Million | -0.118x | +79.02% |
| 2020-06-30 | $5.64 Million | $-3.16 Million | -0.561x | -220.48% |
| 2019-06-30 | $7.35 Million | $-1.29 Million | -0.175x | +57.86% |
| 2018-06-30 | $8.44 Million | $-3.50 Million | -0.415x | +61.17% |
| 2017-06-30 | $6.57 Million | $-7.03 Million | -1.069x | -40.75% |
| 2016-06-30 | $4.94 Million | $-3.75 Million | -0.760x | -20.99% |
| 2015-06-30 | $4.81 Million | $-3.02 Million | -0.628x | -60.80% |
| 2014-06-30 | $6.79 Million | $-2.65 Million | -0.391x | +97.23% |
| 2013-06-30 | $144.99K | $-2.05 Million | -14.108x | -1074.35% |
| 2012-06-30 | $2.05 Million | $-2.46 Million | -1.201x | -5.67% |
| 2011-06-30 | $1.73 Million | $-1.97 Million | -1.137x | -69.19% |
| 2010-06-30 | $3.36 Million | $-2.26 Million | -0.672x | -105.99% |
| 2009-06-30 | $-184.87K | $-2.07 Million | 11.209x | +699.89% |
| 2008-06-30 | $1.11 Million | $-2.07 Million | -1.868x | -23.80% |
| 2007-06-30 | $1.98 Million | $-2.99 Million | -1.509x | -181.71% |
| 2006-06-30 | $5.24 Million | $-2.81 Million | -0.536x | -112.46% |
| 2005-06-30 | $6.96 Million | $-1.76 Million | -0.252x | +16.78% |
| 2004-06-30 | $4.08 Million | $-1.24 Million | -0.303x | +0.21% |
| 2002-06-30 | $6.32 Million | $-1.92 Million | -0.304x | -36.77% |
| 2001-06-30 | $7.48 Million | $-1.66 Million | -0.222x | -- |
About Immuron Ltd ADR
Immuron Limited, a biopharmaceutical company, engages in the research, development, and commercialization of polyclonal antibodies in Australia, the United States, and Canada. It operates through two segments, Research and Development; and Hyper-immune Products. The company offers Travelan, an over-the-counter medicine to reduce the risk of travelers' diarrhea and risk of minor gastrointestinal d… Read more